Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- primeiro trimestre da gestação
- sangramento vaginal
- tamanho uterino incomum para a idade gestacional
Outros fatores diagnósticos
- pré-eclâmpsia de início precoce
- dispneia e desconforto respiratório
- náuseas e vômitos intensos
- taquicardia, tremor, insônia e diarreia
- palidez
- dor pélvica
- sangramento uterino
Fatores de risco
- extremidades etárias maternas
- gravidez molar prévia
- gordura e caroteno reduzidos na dieta
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- exame histológico do tecido placentário
- gonadotrofina coriônica humana (hCG) sérica
- ultrassonografia pélvica
Investigações a serem consideradas
- Hemograma completo
- tempo de protrombina (TP), tempo de tromboplastina parcial (TTP) séricos
- perfil metabólico sérico
- hormônio estimulante da tireoide (TSH) sérico
- tipagem sanguínea com rastreamento de anticorpos
- radiografia torácica
Algoritmo de tratamento
gravidez molar única: pacientes que desejam manter a fertilidade
gravidez molar única: pacientes que não desejam manter a fertilidade
feto gêmeo viável: interrupção eletiva não desejada
feto gêmeo viável: interrupção eletiva
após o manejo inicial: alto risco de neoplasia trofoblástica gestacional com conclusão do acompanhamento improvável
Colaboradores
Autores
Antonio Braga, MD
Associate Professor
Department of Obstetrics and Gynecology
Rio de Janeiro Federal University
Department of Maternal Child
Fluminense Federal University
Rio de Janeiro
Brazil
Disclosures
AB is an author of references cited in this topic.
Kevin M. Elias, MD
Assistant Professor
Brigham and Women’s Hospital
Dana Farber Cancer Institute
New England Trophoblastic Disease Center
Division of Gynecologic Oncology
Department of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School
Boston
MA
Disclosures
KME has been a paid consultant for AOA Dx and received research support from Aspira Women’s Health and Abcam, Inc. KME is an author of references cited in this topic.
Neil S. Horowitz, MD
Associate Professor
Brigham and Women’s Hospital
Dana Farber Cancer Institute
New England Trophoblastic Disease Center
Division of Gynecologic Oncology
Department of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School
Boston
MA
Disclosures
NSH is an author of references cited in this topic.
Ross S. Berkowitz, MD
William H. Baker Professor of Gynecology
Brigham and Women’s Hospital
Dana Farber Cancer Institute
New England Trophoblastic Disease Center
Division of Gynecologic Oncology
Department of Obstetrics, Gynecology and Reproductive Biology
Harvard Medical School
Boston
MA
Disclosures
RSB is an author of references cited in this topic.
Acknowledgements
Dr Ross S. Berkowitz, Dr Kevin M. Elias, Dr Neil S. Horowitz, and Dr Antonio Braga would like to gratefully acknowledge Dr John Soper and Dr Emma Rossi, previous contributors to this topic. JS and ER declare that they have no competing interests.
Peer reviewers
Jane Stewart, PhD, MSc
Consultant Gynecologist
Subspecialist in Reproductive Medicine
Newcastle Fertility Centre at Life
Bioscience Centre
International Centre at Life
Newcastle upon Tyne
UK
Disclosures
JS declares that she has no competing interests.
Philip Savage, PhD, FRCP
Consultant in Medical Oncology
Department of Medical Oncology
Charing Cross Hospital
London
UK
Disclosures
PS declares that he has no competing interests.
Aparna Sundaram, DO, MBA, MPH
Physician Consultant
Preventive Medicine
Private Practice
Atlanta
GA
Disclosures
AS declares that she has no competing interests.
Differentials
- Hiperêmese gravídica
- Aborto espontâneo
- Gestação múltipla
More DifferentialsGuidelines
- Diagnosis and treatment of gestational trophoblastic disease
- Epidemiology, diagnosis, and treatment of gestational trophoblastic disease
More Guidelines
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer